- Home
- AUUD vs QLGN Comparison
AUUD vs QLGN Comparison
Compare AUUD & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- QLGN
- Stock Information
- Founded
- AUUD 2012
- QLGN 1996
- Country
- AUUD United States
- QLGN United States
- Employees
- AUUD N/A
- QLGN N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- QLGN Health Care
- Exchange
- AUUD Nasdaq
- QLGN Nasdaq
- Market Cap
- AUUD 2.7M
- QLGN 2.4M
- IPO Year
- AUUD 2021
- QLGN N/A
- Fundamental
- Price
- AUUD $0.38
- QLGN $3.55
- Analyst Decision
- AUUD
- QLGN
- Analyst Count
- AUUD 0
- QLGN 0
- Target Price
- AUUD N/A
- QLGN N/A
- AVG Volume (30 Days)
- AUUD 5.0M
- QLGN 110.9K
- Earning Date
- AUUD 03-31-2025
- QLGN 04-07-2025
- Dividend Yield
- AUUD N/A
- QLGN N/A
- EPS Growth
- AUUD N/A
- QLGN N/A
- EPS
- AUUD N/A
- QLGN N/A
- Revenue
- AUUD N/A
- QLGN N/A
- Revenue This Year
- AUUD N/A
- QLGN N/A
- Revenue Next Year
- AUUD N/A
- QLGN N/A
- P/E Ratio
- AUUD N/A
- QLGN N/A
- Revenue Growth
- AUUD N/A
- QLGN N/A
- 52 Week Low
- AUUD $0.38
- QLGN $2.96
- 52 Week High
- AUUD $5.70
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- AUUD 39.50
- QLGN 47.06
- Support Level
- AUUD $0.43
- QLGN $3.16
- Resistance Level
- AUUD $0.86
- QLGN $3.75
- Average True Range (ATR)
- AUUD 0.08
- QLGN 0.21
- MACD
- AUUD -0.00
- QLGN 0.06
- Stochastic Oscillator
- AUUD 0.75
- QLGN 67.25
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.